

## CORPORATE ACTION NOTICE

London Market

Notice No. CA/2012/291/Lo

Issue Date:

25 September 2012

Effective Date:

To be announced

**Flexible Individual Equity Option Contract (201F)**

**XCW, XCO, XCB, XCV**

**Flexible Universal Stock Futures Contract (66F)**

**XCF, XCK**

### MEDIQ NV TAKEOVER

This Notice is issued pursuant to the Corporate Actions Policy for the Euronext Derivatives Markets which is available on the NYSE Euronext website at [globalderivatives.nyx.com/regulation/nyse-liffe](http://globalderivatives.nyx.com/regulation/nyse-liffe). It requires the immediate attention of Members' staff involved with the trading and settlement of equity products on these markets. Members should ensure that clients are made aware of the arrangements detailed in this Notice.

**Please Note: This Notice replaces CA/2012/289/Lo.**

1. **Background:** Advent International has announced its intention to launch a cash offer for all of the MediQ NV shares, at an offer price of € 13.25 per share ("the Offer").
2. **ISIN:** NL0009103530.
3. **Effective Date:** To be announced.
4. **Contract Adjustments:**
  - Fair Value Method.
  - Provided that the Offer becomes effective, the contracts shall be de-listed with immediate effect. The contracts will be settled using the Fair Value method. In determining the Fair Value the following will apply:

#### Options:

- **Implied Volatilities:** Given that there is no open interest, no implied volatilities have been calculated. Further series shall be introduced, and their implied volatilities shall be calculated, in accordance with London Notice [No. 3619](#).
- **Dividends:** The dividends as shown in the attachment will be used in determining the Fair Value, if the stated ex-dividend date has not passed.
- **Interest Rates:** Euribor interest rates shall be used in determining the Fair Value prices.

**CORPORATE ACTION NOTICE**

**Futures:**

- **Dividends:** The dividends as shown in the attachment will be used in determining the Fair Value, if the stated ex-dividend date has not passed.
- **Interest Rates:** Euribor interest rates shall be used in determining the Fair Value prices.

For further information in relation to this Notice and/or the Corporate Action Services (“CAS”) provided by NYSE Liffe in respect to OTC Derivatives, Members should contact:

<b>NYSE Liffe:</b> Quality of Derivative Markets	+31 (0) 20 550 4296	Corporateactionsteam@nyx.com Web: <a href="#">Corporate Actions</a>
<b>NYSE Liffe:</b> Corporate Action Services	+31 (0) 20 550 4296	CAServices@nyx.com Web: <a href="#">CAS</a>
<b>NYSE Liffe Clearing:</b> Business Operations	+44 (0)20 7379 2656	nyseliffeclearing@nyx.com Web: <a href="#">NYSE Liffe Clearing</a>

**Mediq NV**

Corporate Action: **Takeover**

**Dividends Mediq NV:**

<b>Dividend amount in: €</b>	<b>Ex-date</b>
0.34	15 Apr 2013
0.16	30 Jul 2013
0.37	15 Apr 2014
0.175	30 Jul 2014
0.385	15 Apr 2015
0.185	30 Jul 2015
0.435	15 Apr 2016